Gain confidence in planning for your future! Join us on November 6th to learn more about care management services, home care options, and long-term care.
Get your questions answered so you can feel optimistic about the future. Click HERE to register online!
The first subcutaneous (under the skin) 24-hour infusion of foslevodopa/foscarbidopa under the brand name Vyalev, was approved by the Food and Drug Administration on Oct 17, 2024.
